Fulgent Genetics, INC 8-K filings

Fulgent Genetics announced its second quarter 2026 financial results, reporting $85.4 million in revenue and a GAAP net loss of $29.5 million, while revising annual revenue guidance.

Fulgent Genetics announced interim Phase 2 results for FID-007 in head and neck cancer, showing a 60% objective response rate and significantly improved progression-free survival compared to standard care.

Fulgent Genetics stockholders approved the 2026 Equity Incentive Plan at the annual meeting, replacing the prior plan and authorizing new share issuances.

Fulgent Genetics, through its subsidiary Inform Diagnostics, has completed the acquisition of Bako Diagnostics and StrataDx for a combined cash purchase price of approximately $56.9 million.

Fulgent Genetics announced its Q4 and full-year 2025 financial results, reporting revenue growth in its laboratory services and progress in its therapeutic pipeline, while providing 2026 guidance.

Fulgent Genetics expands its laboratory services with the acquisition of Bako Diagnostics and StrataDx for a combined $55.5 million in cash.

Fulgent Genetics announced robust third-quarter 2025 financial results, including 17% year-over-year revenue growth and increased full-year guidance.

Fulgent Genetics announced encouraging preliminary Phase 2 clinical data for its drug candidate FID-007 in combination with cetuximab for recurrent or metastatic head and neck squamous cell carcinoma.

Fulgent Genetics announced its second quarter 2025 financial results, reporting a 16% year-over-year increase in core revenue and raising its full-year core revenue guidance, despite experiencing higher GAAP and non-GAAP losses for the quarter.

Fulgent Genetics successfully held its 2025 Annual Meeting of Stockholders, electing directors and ratifying the appointment of Deloitte & Touche LLP as the company's auditor.

Fulgent Genetics announces its first quarter 2025 financial results, highlighting a 16% year-over-year increase in core revenue to $73.5 million and reiterating its full-year core revenue guidance of $310 million.

Fulgent Genetics announces its Q4 and full year 2024 financial results, highlighting core revenue growth but also reporting GAAP losses and providing 2025 guidance.

Fulgent Genetics announced a 9% year-over-year increase in core revenue to $71.7 million for the third quarter of 2024 and improved its full-year earnings per share guidance.

Fulgent Genetics announced its Q2 2024 financial results, showing a 5% year-over-year growth in core revenue to $70.2 million, while also reporting a GAAP loss of $8.7 million.

Fulgent Genetics held its 2024 Annual Meeting of Stockholders, electing directors and ratifying the appointment of Deloitte & Touche LLP as its independent auditor.

Fulgent Genetics announced its Q1 2024 financial results, showing a slight increase in core revenue but a GAAP loss, while reiterating its full-year core revenue guidance.

Fulgent Genetics announced its fourth quarter and full year 2023 financial results, highlighting significant core revenue growth but also reporting GAAP losses.